IRRA Stock Overview
Trades in laboratory and pharmaceutical equipment, and medical devices in Indonesia.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 1/6 |
PT Itama Ranoraya Tbk Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | Rp476.00 |
| 52 Week High | Rp1,045.00 |
| 52 Week Low | Rp436.00 |
| Beta | 0.94 |
| 1 Month Change | 0% |
| 3 Month Change | -2.46% |
| 1 Year Change | -20.67% |
| 3 Year Change | -72.88% |
| 5 Year Change | n/a |
| Change since IPO | -15.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| IRRA | ID Healthcare | ID Market | |
|---|---|---|---|
| 7D | 1.7% | -0.05% | -1.1% |
| 1Y | -20.7% | 5.4% | -1.1% |
Return vs Industry: IRRA underperformed the ID Healthcare industry which returned 5.2% over the past year.
Return vs Market: IRRA underperformed the ID Market which returned -1.3% over the past year.
Price Volatility
| IRRA volatility | |
|---|---|
| IRRA Average Weekly Movement | 10.1% |
| Healthcare Industry Average Movement | 5.8% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in ID Market | 12.7% |
| 10% least volatile stocks in ID Market | 2.5% |
Stable Share Price: IRRA's share price has been volatile over the past 3 months.
Volatility Over Time: IRRA's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of ID stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 212 | Heru Syarif | www.itama.co.id |
PT Itama Ranoraya Tbk trades in laboratory and pharmaceutical equipment, and medical devices in Indonesia. The company offers in vitro diagnostics products comprising rapid test and clinical laboratory; imaging products, including ultrasound, bone densitometer, C-arm, flat panel digital detector, mobile and stationary x-ray, and mammography; cardiovascular, urology, and surgical products; and hospital supplies. It also provides cold chain management, such as cold room and vaccine, bloodbank, and pharmaceutical refrigerator; critical care; and pharmaceutical supplements, as well as maternal and neonatal care products.
PT Itama Ranoraya Tbk Fundamentals Summary
| IRRA fundamental statistics | |
|---|---|
| Market cap | Rp717.72b |
| Earnings (TTM) | Rp3.03b |
| Revenue (TTM) | Rp747.11b |
236.6x
P/E Ratio1.0x
P/S RatioIs IRRA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IRRA income statement (TTM) | |
|---|---|
| Revenue | Rp747.11b |
| Cost of Revenue | Rp605.02b |
| Gross Profit | Rp142.09b |
| Other Expenses | Rp139.06b |
| Earnings | Rp3.03b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.01 |
| Gross Margin | 19.02% |
| Net Profit Margin | 0.41% |
| Debt/Equity Ratio | 44.4% |
How did IRRA perform over the long term?
See historical performance and comparison